Could a multiple sclerosis drug help people with parkinsonism walk better?
NCT ID NCT07682428
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study looks at whether dalfampridine, a drug already used for walking problems in multiple sclerosis, can improve mobility in people with vascular parkinsonism or Parkinson-plus syndromes. Participants who do not respond well to standard levodopa treatment will receive dalfampridine or continue usual care for four weeks. Researchers will measure changes in walking speed, balance, and daily function to see if the drug helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dalfampridine
- What this could lead to
- If successful, this could point toward a new treatment option for mobility problems in people with vascular parkinsonism or related conditions.
- What could go wrong
- This is a small, early exploratory study. The results may not apply to everyone, and dalfampridine can cause side effects like seizures or dizziness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASCULAR PARKINSONISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tangdu Hospital, Fourth Military Medical University
Xi'an, Shaanxi, 710038, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.